by admin- Monday, July 1st, 2019 05:04:11 PM

Alembic Pharma receives USFDA nod for Clonazepam orally disintegrating drugs
Alembic Pharmaceuticals has introduced that the Company has acquired approval from the USA Food & Drug Administration (USFDA) for its Abbreviated New Drug Application
(ANDA) Clonazepam Orally Disintegrating Tablets USP, zero.One hundred twenty five mg, zero.25 mg, 0.5 mg, 1 mg and a couple of mg. The authorised ANDA is therapeutically equal to the reference listed drug (RLD), Klonopin Orally Disintegrating Tablets, zero.A hundred twenty five mg, 0.25 mg, zero.Five mg, 1 mg and 2 mg, of Hoffmann-La Roche, Inc. (Roche). Clonazepam orally disintegrating tablet is useful alone or as an adjunct within the treatment of the Lennox-Gastaut syndrome (petit mal variation), akinetic and myoclonic seizures. In patients with absence seizures (petit mal) who’ve did not respond to succinimides, clonazepam orally disintegrating tablets may be useful. It is also indicated for the treatment of panic sickness, without or with agoraphobia, as described in DSMV.

Clonazepam Orally Disintegrating Tablets USP has an anticipated marketplace size of US$ 20 million for 365 days finishing December 2018 in step with IQVIA.

Alembic now has a complete of 98 ANDA approvals (86 final approvals and 12 tentative approvals) from USFDA.
Strides Pharma Science up on sale of investments in Arrow
Strides Pharma Science introduced that its step down subsidiary in Singapore, Strides Pharma Global has signed the definitive agreements on the market of its investment in Arrow for AUD 392 million.

The Company expects the transaction to close on or round 10 July 2019. SPG will acquire AUD 300 million right now at remaining and balance AUD 94 million can be obtained as deferred consideration sponsored via a secured interest-bearing device.

News Updates